SCHEMBL2807350

SCHEMBL2807350

COCCCn1nc(C)c2ccc(C(=O)OC)cc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
REN P00797 5/20 0.48
SLC22A12 Q96S37 4/20 0.46
KMO O15229 1/20 0.45
GAA P10253 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
PKM P14618 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
SCARB1 Q8WTV0 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
PTGER4 P35408 1/20 0.40
NR3C1 P04150 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2811756 0.88 ALDH1A1 (0.44) RENGAAKDM4EALDH1A1GLA
SCHEMBL15417889 0.87 REN (0.45) RENGAAKDM4EALDH1A1GLA
SCHEMBL2804890 0.87 ALDH1A1 (0.46) RENGAAKDM4EALDH1A1GLA
SCHEMBL2808772 0.86 CFD (0.42) RENGAAKDM4EALDH1A1GLA
SCHEMBL31746474 0.86 KMO (0.46) SLC22A12KMOGAAKDM4EALDH1A1
SCHEMBL2806227 0.84 PKM (0.41) RENGAAKDM4EALDH1A1GLA
SCHEMBL6305577 0.83 SLC22A12 (0.50) SLC22A12KMOGAAKDM4EALDH1A1
SCHEMBL31173820 0.83 SLC22A12 (0.43) RENSLC22A12KMOGAAKDM4E
SCHEMBL31746397 0.83 SLC22A12 (0.43) RENSLC22A12KMOGAAKDM4E
SCHEMBL31746603 0.82 KMO (0.46) SLC22A12KMOGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 REN 1/4885SLC22A12 2804/4885KMO 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.